LJPC Projected Dividend Yield
Com Par $.0001 2014/La Jolla Pharmaceutical Co. ( NASDAQ : LJPC )La Jolla Pharmaceutical is focused on the commercialization of therapies. GIAPREZA™ (angiotensin II) injection is a vasoconstrictor indicated to increase blood pressure in adults with septic or other distributive shock. XERAVA™ (eravacycline) for injection is a tetracycline class antibacterial indicated for the treatment of complicated intra-abdominal infections. Co. owns various product candidates that are in preclinical development including: TP-6076, an IV formulation of a synthetic fluorocycline derivative for the treatment of certain multidrug-resistant gram-negative bacteria; and TP-2846, an IV formulation of a tetracycline for the treatment of acute myeloid leukemia. 20 YEAR PERFORMANCE RESULTS |
LJPC Dividend History Detail LJPC Dividend News LJPC Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |